SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharmaceuticals reports consolidated net loss of Rs 118 crore in Q4

26 May 2022 Evaluate

Torrent Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2022.

The company has reported fall of 20.79% in its net profit at Rs 221 crore for the quarter under review as compared to Rs 279 crore for the same quarter in the previous year. Total income of the company increased by 10.52% at Rs 1723 crore for Q4FY22 as compared Rs 1559 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported net loss at Rs 118 crore for the quarter under review as compared to net profit of Rs 324 crore for the same quarter in the previous year. However, total income of the company increased by 10.68% at Rs 2187 crore for Q4FY22 as compared Rs 1976 crore for the corresponding quarter previous year.

For the year ended March 31, 2022, the company has reported fall of 12.92% in its net profit at Rs 991 crore as compared to Rs 1138 crore for the previous year. However, total income of the company increased by 5.74% at Rs 6946 crore for year under review as compared to Rs 6569 crore for year ended March 31, 2021.

For the year ended March 31, 2022, on the consolidated basis, the company has reported fall of 37.94% in its net profit at Rs 777 crore as compared to Rs 1252 crore for the previous year. However, total income of the company increased by 7.98% at Rs 8705 crore for year under review as compared to Rs 8062 crore for year ended March 31, 2021.

Torrent Pharma Share Price

4178.85 22.50 (0.54%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×